Asset Type: Application brochures and briefs
October 29, 2024 | Rare disease
Application brief — Comprehensive human genomic variant detection with HiFi long-read sequencing
April 11, 2024 | Metagenomics
Application brief — Microbial genomics at scale with PacBio HiFi sequencing
December 20, 2023 | Cancer research
Application brief — HiFi sequencing enables greater accuracy of somatic variant calling
December 11, 2023 | Gene therapy + editing
Application brief — Highly-accurate HiFi reads gene editing
December 4, 2023 | Gene therapy + editing
Application brief — Highly-accurate HiFi reads for AAV-research
October 18, 2023 | Products, procedures + protocols
Application brief — Germline variant detection with the Onso system
August 24, 2023 | Products, procedures + protocols
Application brief — What can you do with a Revio system
August 8, 2023 | Liquid biopsy
Application brief — Superior sensitivity for ctDNA detection on the Onso System
June 22, 2023 | Metagenomics
Application brief — Taxonomic and functional profiling with HiFi metagenomics
March 17, 2023 | Targeted sequencing
Application brief — Scalable HiFi sequencing with Twist Bioscience long-read alliance panels
June 9, 2022 | Sequencing methods
Application brief — HiFi target enrichment with Twist probes
With HiFi target enrichment you can easily and cost-effectively sequence just the genes you care about at scale. Design custom gene panels with our partners at Twist, sequence them with long and accurate HiFi reads, and get all the benefits you expect from HiFi reads: comprehensive detection of single nucleotide variants, structural variants, and indels. HiFi target enrichment is the only technology that can resolve complex gene families like HLA or Cytochrome P450 genes with haplotype resolution.
May 26, 2022 | Sequencing methods
Application brief — HIFI WGS at scale on the Sequel IIe system
Scale your whole genome sequencing (WGS) and epigenome workflows with PacBio® HiFi reads employing a single technician working one day a week. Sequence 25 human genomes at ≥ 30-fold coverage each month using four Sequel® II systems.*